Wednesday, March 25th, 2020
Topic: “Using AI and a Multiomics Approach for Early Detection of Cancer”
Speaker: Jimmy Lin, M.D., Ph.D., MHS
Chief Scientific Officer
Freenome
Location: The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at www.hisfo.com
Price: $50 before 9PM, Monday, March 23rd
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fee will be added to the pre-registration price
6:00 PM – networking
7:00 PM – dinner
8:00 PM – presentation
Abstract:
For the eight most common cancers, starting elective treatment during stage 1 or 2 has demonstrated 10-year survival rates of 80% to 90%. Unfortunately, current screening approaches often fail to detect cancer until significant progression has already occurred.
To address this unmet need, blood tests to enable the early detection of cancer are under development. An approach being taken by Freenome goes beyond mutations, incorporating a multidimensional view of both tumor- and immune-derived signatures. The platform integrates assays for cell-free DNA and RNA, methylation, and proteins with advanced computational biology and machine learning techniques to understand additive signatures for early cancer detection. By training on thousands of cancer-positive blood samples, this multiomics platform learns which biomarker patterns signify a cancer’s stage, type, and most e?ective treatment pathways. Training on healthy samples also helps establish what a normal composition of cell-free biomarkers should look like.
Jimmy Lin will speak about Freenome’s multiomics platform that involves analyzing these circulating biomarkers, using AI to decode billions of complex patterns associated with disease, developing blood tests that can detect cancer before symptoms occur, and using these data to help predict which therapy is most likely to work.
Biography:
In his role as Freenome’s Chief Scientific Officer, Jimmy is responsible for scientific strategy, research operations, and growing the company’s world-class scientific team. He brings a proven record of translating cutting-edge research into commercial success, with a focus on the development and launch of blood-based assays for cancer monitoring and detection of molecular residual disease.
Prior to joining the private sector as CSO for Oncology at Natera, a global genomic diagnostics company, Dr. Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he spearheaded the computational analyses of the first-ever exome sequencing studies in multiple cancer types.
Dr. Lin holds an MD and a PhD in Cellular and Molecular Medicine from Johns Hopkins School of Medicine, as well as a Master of Health Sciences in Bioinformatics from Johns Hopkins School of Public Health. As an undergraduate at Yale, he majored in Cognitive Science and Molecular Biophysics & Biochemistry. Dr. Lin was a 2016 Senior TED Fellow and is the Founder and President of the Rare Genomics Institute.
Event Information
Event Topic:
“Using AI and a Multiomics Approach for Early Detection of Cancer”
Event Description:
Date/Time:
Date(s) - 03/25/20
6:00 pm - 9:00 pm
Event Location:
NOVA - 505 West Olive Ave, Sunnyvale- Suite 799:
Event Details
Event Type